Investors cheered as Dolan predicted 28% earnings growth for 2003, Chief Financial Officer Andrew Bonfield assured that the company's numbers are solid and new Chief Scientific Officer James Palmer outlined a pipeline of drugs that might allow Bristol (nyse: BMY - news - people ) to weather another round of patent expirations.